Holen Sie sich die Stockscreener-App
24.31
0.61%
-0.11
Schlusskurs vom Vortag:
$24.42
Offen:
$24.36
24-Stunden-Volumen:
245.30K
Relative Volume:
0.06
Marktkapitalisierung:
$4.33B
Einnahmen:
$644.86M
Nettoeinkommen (Verlust:
$196.05M
KGV:
24.78
EPS:
0.9812
Netto-Cashflow:
$317.50M
1W Leistung:
-7.79%
1M Leistung:
-11.42%
6M Leistung:
-4.79%
1J Leistung:
-65.08%
1-Tages-Spanne:
$23.95
$24.57
1-Wochen-Bereich:
$23.95
$27.32
52-Wochen-Spanne:
$17.15
$76.51
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Compare DOCS vs VEEV, BTSG, TEM, TXG, HQY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
24.28 | 4.35B | 644.86M | 196.05M | 317.50M | 0.9812 |
VEEV
Veeva Systems Inc
|
262.47 | 42.88B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.30 | 12.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
62.65 | 11.67B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
64.14 | 8.55B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
93.54 | 7.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Truist | Buy → Hold |
| 2026-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-02-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2026-02-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-20 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-01-08 | Hochstufung | Truist | Hold → Buy |
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Doximity (NYSE:DOCS) Stock Rating Lowered by Freedom Capmkts - MarketBeat
Doximity stock falls as Freedom Capital cuts to hold - Investing.com
Doximity stock rating cut to Hold by Freedom Capital on margin concerns - Investing.com Australia
Doximity, Inc. $DOCS Shares Sold by Carmignac Gestion - MarketBeat
Doximity (NYSE:DOCS) Trading Down 7.1%Time to Sell? - MarketBeat
Doximity stock downgraded at Freedom Capital (DOCS:NYSE) - Seeking Alpha
DOCS Downgraded by Freedom Capital Markets -- Price Target Raised to $27.00 - GuruFocus
Why is Doximity stock slipping today? By Investing.com - Investing.com Canada
Doximity (NYSE:DOCS): Is the Inflation Test Bigger Than It Looks? - Kalkine Media
Doximity, Inc. (DOCS) Stock Analysis: Navigating a 13% Potential Upside Amidst Healthcare Innovation - DirectorsTalk Interviews
Why GitLab Stock Soared 35% in August and Why It's Already Rocketed Higher - The Motley Fool
Doximity, Inc. (DOCS) Stock Analysis: Navigating a 17.56% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Is It Time To Consider Buying Doximity, Inc. (NYSE:DOCS)? - Moomoo
AXQ Capital LP Has $3.67 Million Stake in Doximity, Inc. $DOCS - MarketBeat
Doximity, Inc. $DOCS Shares Purchased by Wellington Management Group LLP - MarketBeat
Doximity (DOCS) 10K Form and Latest SEC Filings 2026 - MarketBeat
Could Doximity (NYSE:DOCS) Gain Focus Within the NYSE Composite? - Kalkine Media
Doximity (NYSE:DOCS): A Quality Investment with Superior Returns on Capital - ChartMill
Director at Doximity (NYSE: DOCS) lines up 2,000-share sale - Stock Titan
3 Reasons to Avoid DOCS and 1 Stock to Buy Instead - Yahoo Finance
Doximity, Inc. (DOCS): Investor Outlook Reveals 11.40% Potential Upside Amidst Strong Market Dynamics - DirectorsTalk Interviews
Fundsmith LLP Has $13.55 Million Stake in Doximity, Inc. $DOCS - MarketBeat
Doximity (DOCS) Is Up 5.5% After AI Optimism Lifts Enterprise SaaS Peers' Results What's Changed - Sahm
Doximity Inc (DOCS) Shares Surge 4.5% -- What GF Score of 86 Tel - GuruFocus
Doximity (NYSE:DOCS) Trading Up 4.5%What's Next? - MarketBeat
Amplitude, GitLab, Doximity, Freshworks, and Sprinklr Shares Skyrocket, What You Need To Know - Yahoo Finance
Doximity Inc (DOCS) Shares Surge 3.4% -- What GF Score of 82 Tel - GuruFocus
Odyssean LLC Invests $2.38 Million in Doximity, Inc. $DOCS - MarketBeat
Doximity (NYSE: DOCS) director to sell 2,000 shares in 2026 - Stock Titan
Nearly Half of Doctors Say They May Quit Within 2 Years. New Tools Are Helping Ease Burnout - inc.com
Reasons to Retain Doximity Stock in Your Portfolio for Now - Yahoo Finance
Doximity, Inc. (NYSE:DOCS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Doximity (NYSE:DOCS) Given New $27.00 Price Target at Barclays - MarketBeat
A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here's What to Know - AOL.com
DOXIMITY : BARCLAYS RAISES TARGET PRICE TO $27 FROM $20 - Bitget
Doximity (DOCS) Latest Quarter: Profit Per Share Falls Below Its Benchmark at the Close; Stock Move: The Market Price Moves 3.25% Higher in Latest TradingRevenue Guidance Update - Vinanet
Doximity (DOCS) Latest Quarter: Profit Per Share Falls Below Its Benchmark at the Close; Stock Move - Vinanet
SK Hynix, SpaceX, Doximity, Trade Desk, Rigetti, Coherent, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Doximity (DOCS) Results Breakdown: EPS Does Not Reach the Reported Estimate in the Reported Period; Post-Report: Shares Rise 3.25% on the DayEarnings Beat Streak - Vinanet
Doximity (DOCS) Stock Looks Cheap On Cash Flow Yet Fair On Earnings - Yahoo Finance
Doximity (DOCS) Stock Could Be 31% Undervalued Following Raised AI Outlook - simplywall.st
Doximity (DOCS) Q1 2027 Earnings Call Transcript - AOL.com
Doximity (DOCS) Could Be 26% Below Fair Value On Strong Earnings Guidance - Yahoo Finance
Doximity (NYSE:DOCS) Valuation Debate Gets More Interesting - Kalkine Media
What Investors Should Know of This Doximity Officer's Latest Insider Transaction - The Motley Fool
Doximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors - The Motley Fool
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know. - The Motley Fool
Doximity's Co-Founder Just Filed a Form 4. Is There Anything in It Worth Worrying About? - The Motley Fool
Is Doximity (DOCS) Turning Rising AI Revenue Into Sustainable Profits Or Margin Trade-Offs? - webull.com
Doximity CAO Siddharth Sitaram sells $44,143 of class A stock By Investing.com - Investing.com South Africa
Doximity CAO Siddharth Sitaram sells $44,143 of class A stock - Investing.com
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):